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Valve selection in the patient with a small aortic root remains adifficult decision for cardiac surgeons. Use of smaller stentedporcine tissue valves in these patients may result in high gradientsand low effective orifice areas.1,2 In some cases, there may beprosthesis-patient mismatch,3 which can result in persistent leftventricular hypertrophy after valve replacement and has been
reported in up to 52% of patients.4 Jin and colleagues5 found no significant
regression of left ventricular hypertrophy in patients after implantation of either
stented tissue valves or mechanical valves, although patients receiving unstented
tissue valves and homografts did demonstrate significant regression.
Recognition of the potential importance of prosthesis-patient mismatch has led to
interest in developing valve substitutes with improved hemodynamics. Although
much of the recent literature has focused on stentless tissue valves, more traditional
valve designs have also evolved to meet this challenge. The St Jude Medical HP
(High Performance) valve was designed to allow supra-annular placement of the
valve through modification of the sewing ring on a standard St Jude Medical valve.
This allows a valve approximately one size larger to be inserted in the same size
aortic root. Intuitively, one would expect this valve to have lower pressure gradients
possibly resulting in better remodeling of the ventricle and more complete regres-
sion of hypertrophy after valve replacement than the standard cuff (SC) St Jude
Medical valve. However, evidence for an improvement in hemodynamics with the
HP valve has been lacking.
In this issue of the Journal, Vitale and coworkers6 report a randomized, multi-
center trial comparing the postoperative and 6-month hemodynamics between the St
Jude Medical HP and SC valves. The results are interesting on several levels. When
HP and SC valves were compared at 6 months, both peak and mean pressure
gradients were lower in the 21-mm and 23-mm HP valves than in the SC valves of
the same size. However, effective orifice area did not differ significantly between
SC and HP valves. A possible explanation for this finding lies in the greater cardiac
output in the patients with SC valves in this series, which makes it difficult to draw
definitive conclusions about the hemodynamic superiority of HP over SC valves. At
6 months, both the 21-mm and 23-mm HP valves demonstrated similarly low
gradients (mean gradients of 18.8 and 14.9 mm Hg, respectively) and good effective
orifice areas (1.56 cm2 and 1.60 cm2, respectively). These observations suggest that
aortic root enlargement procedures may not be needed to upgrade from a 21-mm HP
valve to a 23-mm HP valve since little additional hemodynamic benefit accrues.
Vitale and coworkers also examined the prevalence of postoperative patient-pros-
thesis mismatch. In contrast to the high prevalence in prior reports noted above, no
patient in this series had patient-prosthesis mismatch according to an effective area
index less than 0.9 cm2/m2, slightly stricter criteria than recommended by Pibarot
and Dumesnil.4
Interestingly, HP valves showed a progressive reduction in gradient and effective
orifice area in serial measurements after implantation. Since the HP valve is
mechanical and fixed in size, no changes in shape or geometry of the valve itself are
possible. This suggests that there may be remodeling either of the outflow tract or
of the distal aorta allowing a closer matching of valve size with either outflow tract
or aortic size. This late reduction in gradient has been reported in several previous
studies with stentless valves.7,8 Vitale’s article demonstrates that this late reduction
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in gradient can occur in St Jude Medical HP valves and
therefore suggests that the underlying process, whether aor-
tic root remodeling or left ventricular outflow tract remod-
eling, can also occur with bileaflet mechanical valves.
The present study leaves open several questions for fu-
ture investigation. The most important clinical sequela of
elevated aortic valve gradients after valve replacement is
incomplete regression left ventricular hypertrophy. De
Paulis and colleagues9 have shown that although regression
of left ventricular hypertrophy does occur with bileaflet
valves, it may be incomplete and result in persistent eleva-
tions in left ventricular mass, primarily as a result of resid-
ual septal thickening. The degree of septal thickness has
also been shown to be an independent predictor of mortality
in patients with aortic stenosis.10 It would be of great
interest to see comparative data on changes in left ventric-
ular mass and septal thickness in the present study and to
determine whether left ventricular mass was more likely to
return to normal in the HP group.
In summary, these findings suggest that the 21-mm and
23-mm St Jude Medical HP bileaflet mechanical valves are
a reasonable choice in the patient with a small aortic root
and did not result in patient-prosthesis mismatch. Ideally,
the ultimate goal of the newer, more hemodynamically
efficient valve designs should be to allow complete regres-
sion of hypertrophy. Further studies are still required to
determine the long-term effects of both stentless and supra-
annular mechanical valves on left ventricular mass, as well
as interactions with patient factors such as genetics11 and
systemic blood pressure.
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